CH Peptides
Every formulation is curated with lab-grade ingredients, and we're syncing up the freshest data from our inventory so you see accurate availability as soon as the app loads.
Loading live inventory
Syncing 24 research sprays
Verifying lab supplies
Supabase + Stripe ready
Orders placed before 2 P.M. PST Monday through Friday are shipped out same day!
Looks like you haven't added any products to your cart yet.
Loading...
BPC-157, an acronym for Body Protection Compound-157, is a pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. While it is often referred to as its BPC code name in scientific literature, it does not have an associated pharmaceutical development code or alternative naming conventions beyond BPC-157.
BPC-157 consists of 15 amino acids, specifically Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It does not derive from a larger parent protein nor does it possess any specific post-translational modifications such as N-terminal acetylation or C-terminal amidation. Its endogenous-like sequence contributes to its stability and resistance to protease degradation.
BPC-157 has been studied for its potential interaction with growth hormone receptor pathways, although specific receptor targets are yet to be fully elucidated. Current studies suggest involvement in angiogenesis and NO pathway modulation. Detailed signaling pathways such as MAPK/ERK, PI3K/Akt, and other angiogenic-related cascades have been indicated, though precise EC50/IC50 values are not well-documented.
BPC-157 is soluble in sterile water and typically recommended at concentrations of 1mg/mL for research applications. It remains stable in lyophilized form at room temperature for extended periods, whereas reconstituted solutions are stable when refrigerated (< 8°C) for short-term use.
For laboratory research use only. Not for human or veterinary use. Not intended for diagnostic, therapeutic, or preventive applications.
BPC-157, an acronym for Body Protection Compound-157, is a pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. While it is often referred to as its BPC code name in scientific literature, it does not have an associated pharmaceutical development code or alternative naming conventions beyond BPC-157.
BPC-157 consists of 15 amino acids, specifically Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It does not derive from a larger parent protein nor does it possess any specific post-translational modifications such as N-terminal acetylation or C-terminal amidation. Its endogenous-like sequence contributes to its stability and resistance to protease degradation.
BPC-157 has been studied for its potential interaction with growth hormone receptor pathways, although specific receptor targets are yet to be fully elucidated. Current studies suggest involvement in angiogenesis and NO pathway modulation. Detailed signaling pathways such as MAPK/ERK, PI3K/Akt, and other angiogenic-related cascades have been indicated, though precise EC50/IC50 values are not well-documented.
BPC-157 is soluble in sterile water and typically recommended at concentrations of 1mg/mL for research applications. It remains stable in lyophilized form at room temperature for extended periods, whereas reconstituted solutions are stable when refrigerated (< 8°C) for short-term use.
For laboratory research use only. Not for human or veterinary use. Not intended for diagnostic, therapeutic, or preventive applications.
Methylene blue, also scientifically known as tetramethylthionine chloride, is a heterocyclic aromatic chemical compound. It is frequently referred to in research by its chemical name and has been used historically in various applications, although specific research codes have not been consistently applied to this compound.
Methylene blue does not consist of an amino acid sequence as it is a phenothiazine derivative. It has a tricyclic phenothiazine structure, featuring a central sulfur and nitrogen atom with methyl substitutions that influence its redox properties. The compound is not derived from a larger protein fragment, but its planar aromatic structure is crucial for its electron transfer capability.
Methylene blue primarily functions by inhibiting the enzyme guanylate cyclase, thus impacting the NO-cGMP pathway. This interference can modulate vascular tone and neurotransmitter release. It has also been noted to act as a redox agent, accepting and donating electrons through alteration in its oxidation states. EC50 values vary depending on the cellular context, but it can modulate several cellular processes via its electron transfer roles.
Methylene blue is highly soluble in water, particularly at concentrations such as 1mg/mL, making it conducive for aqueous applications. Reconstitution is recommended in sterile water or appropriate buffer solutions. Stability data suggest that it remains stable in lyophilized form and must be handled under light-limiting conditions due to its photolabile nature.
For laboratory research use only. Not for human or veterinary use. Not intended for diagnostic, therapeutic, or preventive applications.
The full chemical name for Tesofensine is (3R)-1,3,4,5-tetrahydro-3-[2-(dimethylamino)ethyl]-2-benzofuran-5-ol. It is referred to as NS-2330 in early development stages, and its parent compound is derived from sibutramine, though it is not a direct fragment or analog. Alternative naming in literature includes the designation Tesofensine without additional numeric codes.
Tesofensine is not a peptide and thus lacks an amino acid sequence; it is a small organic molecule without recognizable peptide modifications. However, its molecular conformation is non-linear, with a distinct benzofuran moiety that contributes to its biological activity.
Tesofensine is a potent inhibitor of presynaptic reuptake of norepinephrine, dopamine, and serotonin. It has been shown to act as an indirect agonist at these monoaminergic pathways. Studies indicate that it increases extracellular concentrations of these neurotransmitters, exerting its pharmacological effects through modulation of monoaminergic signaling cascades. The pharmacological profile includes a higher binding affinity for the serotonin transporter (SERT) compared to norepinephrine (NET) and dopamine (DAT) transporters. Precise EC50/IC50 values can vary across studies.
Tesofensine is soluble in DMSO at concentrations exceeding 10mg/mL and requires careful control of solubility conditions during reconstitution. For research purposes, it should be stored as a lyophilized powder in a desiccated environment to ensure stability. Reconstituted solutions are stable for short periods at low temperatures.
For laboratory research use only. Not for human or veterinary use. Not intended for diagnostic, therapeutic, or preventive applications.
The full chemical name for Tesofensine is (3R)-1,3,4,5-tetrahydro-3-[2-(dimethylamino)ethyl]-2-benzofuran-5-ol. It is referred to as NS-2330 in early development stages, and its parent compound is derived from sibutramine, though it is not a direct fragment or analog. Alternative naming in literature includes the designation Tesofensine without additional numeric codes.
Tesofensine is not a peptide and thus lacks an amino acid sequence; it is a small organic molecule without recognizable peptide modifications. However, its molecular conformation is non-linear, with a distinct benzofuran moiety that contributes to its biological activity.
Tesofensine is a potent inhibitor of presynaptic reuptake of norepinephrine, dopamine, and serotonin. It has been shown to act as an indirect agonist at these monoaminergic pathways. Studies indicate that it increases extracellular concentrations of these neurotransmitters, exerting its pharmacological effects through modulation of monoaminergic signaling cascades. The pharmacological profile includes a higher binding affinity for the serotonin transporter (SERT) compared to norepinephrine (NET) and dopamine (DAT) transporters. Precise EC50/IC50 values can vary across studies.
Tesofensine is soluble in DMSO at concentrations exceeding 10mg/mL and requires careful control of solubility conditions during reconstitution. For research purposes, it should be stored as a lyophilized powder in a desiccated environment to ensure stability. Reconstituted solutions are stable for short periods at low temperatures.
For laboratory research use only. Not for human or veterinary use. Not intended for diagnostic, therapeutic, or preventive applications.
RAD-140 (Testolone) is a synthetic selective androgen receptor modulator (SARM) that is investigated in laboratory research to study its interactions with androgen receptors.